WHO recommends second malaria vaccine for children
The World Health Organization (WHO) recommended on Monday a second malaria vaccine for children, which could save hundreds of thousands of lives by plugging a huge supply and demand gap.
“As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” said World Health Organization chief Tedros Adhanom Ghebreyesus.
The new R21/Matrix-M vaccine, developed by Britain’s Oxford University and manufactured by the Serum Institute of India, has already been approved for use in Burkina Faso, Ghana and Nigeria.
In 2021, the RTS,S vaccine, produced by British pharmaceutical giant GSK, became the first to be recommended by the WHO to prevent malaria in children in areas with moderate to high malaria transmission.
“Demand for the RTS,S vaccine far exceeds supply, so this second vaccine is a vital additional tool to protect more children faster, and to bring us closer to our vision of a malaria-free future.” Tedros added.
WHO has pointed out that the RTS,S vaccine will be introduced in some African countries in early 2024, and the R21 vaccine is expected to be available in mid-2024.
Almost half the world’s population lives in a malaria high-risk area, with the vast majority of cases and deaths occurring in Africa. Nearly half a million children in the African region die every year from the disease.
